{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:40:17Z","timestamp":1789958417507,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Triple negative breast cancer (TNBC) is an aggressive subtype, still with limited therapeutic options. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT is widely used in TNBC, but evidence regarding its prognostic value remains limited. The TRINE PET study, promoted by the Italian Association of Nuclear Medicine, aimed to evaluate the prognostic relevance and clinical impact of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT in a large real world TNBC cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective multicenter study included 389 TNBC patients who underwent 707 [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT scans across 23 Italian Nuclear Medicine Units. Clinical settings were baseline staging (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009257 patients), post neoadjuvant chemotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009111 patients), suspected recurrence (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009144 patients), and advanced metastatic disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009195 patients). Progression free survival (PFS) and overall survival (OS) were assessed using Kaplan\u2013Meier and Cox regression analyses. The influence of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT on clinical management was evaluated across all settings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During a median follow up of 34\u00a0months (1\u2013124), disease progression and death occurred in 39.3% and 28.4% of cases, respectively. Across all clinical settings, nodal and distant metastatic involvement at [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT was strongly associated with worse PFS and OS (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In multivariate analysis, distant metastases at [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT resulted the strongest independent predictor of OS (HR 9.42, 95% CI 3.74\u201323.75) and PFS (HR 6.57, 95% CI 3.05\u201314.12), while Ki67 and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake at primary tumor did not. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT findings led to a change in clinical management in 20.8% of all scans, with the highest impact in the advanced metastatic setting (34.9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In the largest real world multicenter study dedicated to TNBC, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT demonstrated robust prognostic value across all disease settings. PET detected metastatic involvement emerged as the most powerful predictor of survival; moreover, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT influenced therapeutic decision in all settings of disease, reaching one in three scans in the advanced metastatic disease. These findings support the systematic integration of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT into the diagnostic pathways of TNBC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08056-1","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:13:11Z","timestamp":1786954391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic relevance of [18F]FDG PET\/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-3898","authenticated-orcid":false,"given":"Luca","family":"Urso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Panareo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Iudicello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Bartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Taralli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Calcagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Mazzoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bonacina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paccagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta Benedetta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Sciuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Garrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrio","family":"Aric\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rovera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Reccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Cassarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Arnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Margherita","family":"Maffione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ialuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Frega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"All the TRINE-PET Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"8056_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31:1154\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"key":"8056_CR2","doi-asserted-by":"publisher","first-page":"102990","DOI":"10.1016\/j.canep.2026.102990","volume":"101","author":"S Fabiano","year":"2025","unstructured":"Fabiano S, Perotti V, Contiero P, Tittarelli A, Pesce MT, Guzzinati S, et al. Estimates of cancer incidence to 2025 in Italy: numbers and rates. Cancer Epidemiol. 2025;101:102990. https:\/\/doi.org\/10.1016\/j.canep.2026.102990.","journal-title":"Cancer Epidemiol"},{"key":"8056_CR3","unstructured":"Associazione Italiana di Oncologia Medica. I Numeri del cancro in Italia 2020. 2020. https:\/\/www.aiom.it\/wp-content\/uploads\/2020\/10\/2020_Numeri_Cancro-operatori_web.pdf"},{"key":"8056_CR4","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdt303.","journal-title":"Ann Oncol"},{"key":"8056_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espi\u00e9 M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426\u201335. https:\/\/doi.org\/10.1007\/s00259-010-1640-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR6","doi-asserted-by":"publisher","first-page":"oyaf034","DOI":"10.1093\/oncolo\/oyaf034","volume":"30","author":"K Punie","year":"2011","unstructured":"Punie K, Kurian AW, Ntalla I, Sjekloca N, Estrin A, Dabrowski EC, et al. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States. Oncologist. 2011;30:oyaf034. https:\/\/doi.org\/10.1093\/oncolo\/oyaf034.","journal-title":"Oncologist"},{"key":"8056_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00259-024-06866-9","volume":"52","author":"L Filippi","year":"2024","unstructured":"Filippi L, Urso L, Ferrari C, Guglielmo P, Evangelista L. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective. Eur J Nucl Med Mol Imaging. 2024;52:263\u201379. https:\/\/doi.org\/10.1007\/s00259-024-06866-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40336-025-00742-8","volume":"14","author":"L Urso","year":"2025","unstructured":"Urso L, Panareo S, Iudicello A, Albano D, Filippi L, Evangelista L. Real-world, multicenter assessment of 18 F-FDG PET\/CT prognostic value in triple-negative breast cancer (TRINE-PET): the study protocol. Clin Transl Imaging. 2025;14:59\u201364. https:\/\/doi.org\/10.1007\/s40336-025-00742-8.","journal-title":"Clin Transl Imaging"},{"key":"8056_CR9","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.eanmj.2025.100006","volume":"1","author":"R Boellaard","year":"2025","unstructured":"Boellaard R, Herrmann K, Barrington SF, Cranston I, Mottaghy FM, Hoekstra CJ, et al. [18F]FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 3.0. EANM J. 2025;1:100006. https:\/\/doi.org\/10.1016\/j.eanmj.2025.100006.","journal-title":"EANM J"},{"key":"8056_CR10","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332. https:\/\/doi.org\/10.1007\/s00259-024-06696-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR11","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Delord M, Giacchetti S, Hamy A, de Bazelaire C, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879\u201387. https:\/\/doi.org\/10.1093\/jnci\/djs451.","journal-title":"J Natl Cancer Inst"},{"key":"8056_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"key":"8056_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-025-02138-0","author":"R Gerosa","year":"2025","unstructured":"Gerosa R, Gelardi F, Tiberio P, Jacobs F, Benvenuti C, Gaudio M, et al. [18F]FDG PET\/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies? Radiol med. 2025. https:\/\/doi.org\/10.1007\/s11547-025-02138-0.","journal-title":"Radiol med"},{"key":"8056_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00259-014-2941-1","volume":"42","author":"D Groheux","year":"2015","unstructured":"Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al. Prognostic impact of 18F-FDG PET\/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:377\u201385. https:\/\/doi.org\/10.1007\/s00259-014-2941-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.115.163907","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Biard L, Giacchetti S, Teixeira L, Hindi\u00e9 E, Cuvier C, et al. 18F-FDG PET\/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: influence of the chemotherapy regimen. J Nucl Med. 2016;57:536\u201343. https:\/\/doi.org\/10.2967\/jnumed.115.163907.","journal-title":"J Nucl Med"},{"key":"8056_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MNM.0000000000001500","volume":"43","author":"L Urso","year":"2022","unstructured":"Urso L, Quartuccio N, Caracciolo M, Evangelista L, Schirone A, Frassoldati A, et al. Impact on the long-term prognosis of FDG PET\/CT in luminal-A and luminal-B breast cancer. Nucl Med Commun. 2022;43:212\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000001500.","journal-title":"Nucl Med Commun"},{"key":"8056_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/cancers14030637","volume":"14","author":"C Bouron","year":"2022","unstructured":"Bouron C, Mathie C, Seegers V, Morel O, J\u00e9z\u00e9quel P, Lasla H, et al. Prognostic value of metabolic, volumetric and textural parameters of baseline [18F]FDG PET\/CT in early triple-negative breast cancer. Cancers. 2022;14:637. https:\/\/doi.org\/10.3390\/cancers14030637.","journal-title":"Cancers"},{"key":"8056_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2174\/1573405618666220329094423","volume":"19","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Urso L, Caracciolo M, Stracuzzi F, Panareo S, Cistaro A, et al. FDG PET\/CT volume-based quantitative data and survival analysis in breast cancer patients: a systematic review of the literature. Curr Med Imaging. 2023;19:807\u201316. https:\/\/doi.org\/10.2174\/1573405618666220329094423.","journal-title":"Curr Med Imaging"},{"key":"8056_CR19","first-page":"120","volume":"6","author":"B Marinelli","year":"2016","unstructured":"Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, et al. Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6:120\u20137.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"8056_CR20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00259-017-3748-7","volume":"44","author":"Y-I Kim","year":"2017","unstructured":"Kim Y-I, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung J-K, et al. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET\/CT in operable triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1787\u201395. https:\/\/doi.org\/10.1007\/s00259-017-3748-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR21","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial). Radiology. 2024;312:e233460. https:\/\/doi.org\/10.1148\/radiol.233460.","journal-title":"Radiology"},{"key":"8056_CR22","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.31557\/APJCP.2024.25.10.3577","volume":"25","author":"N Fatima","year":"2024","unstructured":"Fatima N, Zaman U, Ahmed A, Zaman S, Khan K, Zaman MU. Impact of 18FDG PET\/CT on clinical management, cost effectiveness, and radiation exposure in newly diagnosed breast cancer patients. Asian Pac J Cancer Prev. 2024;25:3577\u201381. https:\/\/doi.org\/10.31557\/APJCP.2024.25.10.3577.","journal-title":"Asian Pac J Cancer Prev"},{"key":"8056_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","volume":"41","author":"A Cochet","year":"2014","unstructured":"Cochet A, Dygai-Cochet I, Riedinger J-M, Humbert O, Berriolo-Riedinger A, Toubeau M, et al. 18F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428\u201337. https:\/\/doi.org\/10.1007\/s00259-013-2595-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8056_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejso.2009.11.009","volume":"36","author":"TS Aukema","year":"2010","unstructured":"Aukema TS, Rutgers EJTH, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MTFD, et al. The role of FDG PET\/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol (EJSO). 2010;36:387\u201392. https:\/\/doi.org\/10.1016\/j.ejso.2009.11.009.","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"8056_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cpet.2014.12.004","volume":"10","author":"L Lebron","year":"2015","unstructured":"Lebron L, Greenspan D, Pandit-Taskar N. PET imaging of breast cancer. PET Clin. 2015;10:159\u201395. https:\/\/doi.org\/10.1016\/j.cpet.2014.12.004.","journal-title":"PET Clin"},{"key":"8056_CR26","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00259-016-3402-9","volume":"43","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. (18)F-FDG-PET\/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937\u201344. https:\/\/doi.org\/10.1007\/s00259-016-3402-9.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:13:20Z","timestamp":1786954400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":26,"alternative-id":["8056"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08056-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethical committee of the promoting center (Azienda Ospedaliero-Universitaria di Modena, Modena, Italy) on February 13, 2024 (656\/2023\/OSS\/AOUMO \u2013 SIRER ID: 6869). Every participant center has been invited to obtain ethical approval by its local ethical committee. In some cases, a sponsorship agreement has been established between the promotor and the collaborators.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}